Based on the PTC Therapeutics Inc stock forecast from 10 analysts, the average analyst target price for PTC Therapeutics Inc is USD 43.50 over the next 12 months. PTC Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of PTC Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, PTC Therapeutics Inc’s stock price was USD 43.23. PTC Therapeutics Inc’s stock price has changed by +10.20% over the past week, +9.94% over the past month and +99.95% over the last year.
No recent analyst target price found for PTC Therapeutics Inc
No recent average analyst rating found for PTC Therapeutics Inc
Company Overview PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Read Less
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscula...Read More
Frequently Asked Questions About PTC Therapeutics Inc (PTCT) Stock
Based on ratings from 10 analysts PTC Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 9 buy, 4 sell and 7 hold ratings.
Unfortunately we do not have enough data on PTCT's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for PTCT is USD 43.50 over the next 12 months. The maximum analyst target price is USD 64 while the minimum anlayst target price is USD 25.
Unfortunately we do not have enough data on PTCT's stock to indicate if its overvalued.
The last closing price of PTCT's stock was USD 43.23.
The most recent market capitalization for PTCT is USD 3.11B.
Based on targets from 10 analysts, the average taret price for PTCT is projected at USD 43.50 over the next 12 months.
This means that PTCT's stock price may go up by +0.62% over the next 12 months.
We can't find any ETFs which contains PTC Therapeutics Inc's stock.
As per our most recent records PTC Therapeutics Inc has 988 Employees.
PTC Therapeutics Inc's registered address is 100 Corporate Court, South Plainfield, NJ, United States, 07080.
You can get more information about it from PTC Therapeutics Inc's website at https://www.ptcbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About PTC Therapeutics Inc (PTCT) Stock
Based on ratings from 10 analysts PTC Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 9 buy, 4 sell and 7 hold ratings.
Unfortunately we do not have enough data on PTCT's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for PTCT is USD 43.50 over the next 12 months. The maximum analyst target price is USD 64 while the minimum anlayst target price is USD 25.
Unfortunately we do not have enough data on PTCT's stock to indicate if its overvalued.
The last closing price of PTCT's stock was USD 43.23.
The most recent market capitalization for PTCT is USD 3.11B.
Based on targets from 10 analysts, the average taret price for PTCT is projected at USD 43.50 over the next 12 months.
This means that PTCT's stock price may go up by +0.62% over the next 12 months.
We can't find any ETFs which contains PTC Therapeutics Inc's stock.
As per our most recent records PTC Therapeutics Inc has 988 Employees.
PTC Therapeutics Inc's registered address is 100 Corporate Court, South Plainfield, NJ, United States, 07080.
You can get more information about it from PTC Therapeutics Inc's website at https://www.ptcbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PTCT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
